Skip to main content
SpringerLink
Log in

Psoriasis vulgaris: Biologika im Langzeit-Vergleich

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Nachlassende Wirksamkeit ist der Hauptgrund dafür, dass Psoriasispatienten eine Langzeittherapie mit Biologika abbrechen. Gegenüber TNF-α-Blockern ergab sich in einer Studie für Ustekinumab die längste Behandlungsdauer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Gniadecki R et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. BJD 2015; 172; 244–252

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Christine Starostzik

Authors
  1. Christine Starostzik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Starostzik, C. Psoriasis vulgaris: Biologika im Langzeit-Vergleich. hautnah dermatologie 31, 23 (2015). https://doi.org/10.1007/s15012-015-1786-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-015-1786-z

Search

Navigation